Rao D N, Shroff P D, Chattopadhyay G, Dinshaw K A
Division of Epidemiology and Biostatistics, Tata Memorial Hospital, Parel, Mumbai, India.
Br J Cancer. 1998 May;77(9):1514-8. doi: 10.1038/bjc.1998.249.
This is a study of 5595 head and neck cancer patients treated during 1987-89 at TMH, Mumbai. The study included 1970 oral cancers (ICD 140-145), 1495 oropharyngeal cancers (ICD 1410, 1453, 146), 1255 hypopharyngeal cancers (ICD 148), 125 nasopharyngeal cancers (ICD 147) and 750 laryngeal cancers (ICD 161). The clinical extent of disease at presentation was based on TNM group staging (UICC 1978). For the majority of sites, patients attended the hospital during stage III and stage IV of the disease; the only exception was for cancers of the lower lip, anterior tongue and vocal cord when between 46.2% and 56.5% of patients with localized cancer (stage I and II) were seen. Generally, surgery either alone or with radiation has been administered for oral cancer patients whereas radiation either alone or in combination with chemotherapy was administered for other head and neck sites. The overall 5-year survival rate was in the range of 20-43% for oral cancer, 8-25% for pharyngeal cancers and 25-62% for laryngeal cancer. The 5-year relative survival rates were more or less in agreement with the results published by the Eurocare study for head and neck cancers. The importance of primary prevention in head and neck cancer is stressed.
这是一项针对1987年至1989年期间在孟买TMH接受治疗的5595名头颈部癌症患者的研究。该研究包括1970例口腔癌（ICD 140 - 145）、1495例口咽癌（ICD 1410、1453、146）、1255例下咽癌（ICD 148）、125例鼻咽癌（ICD 147）和750例喉癌（ICD 161）。疾病呈现时的临床范围基于TNM组分期（UICC 1978）。对于大多数部位，患者在疾病的III期和IV期就诊；唯一的例外是下唇癌、舌前癌和声带癌，有46.2%至56.5%的局限性癌症（I期和II期）患者前来就诊。一般而言，口腔癌患者单独接受手术或手术联合放疗，而其他头颈部部位单独接受放疗或放疗联合化疗。口腔癌的总体5年生存率在20%至43%之间，咽癌为8%至25%，喉癌为25%至62%。5年相对生存率与欧洲癌症研究（Eurocare）发表的头颈部癌症结果大致相符。强调了头颈部癌症一级预防的重要性。
